Clinical Trials Logo

Metastatic Liver Carcinoma clinical trials

View clinical trials related to Metastatic Liver Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06349642 Recruiting - Clinical trials for Metastatic Malignant Solid Neoplasm

Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform

CYBRID-04
Start date: April 24, 2024
Phase:
Study type: Observational

The primary purpose of this study is to determine the sensitivity of CYBRID Score for predicting in-vivo clinical response based on surgical response or RECIST 1.1 for neoadjuvant and locally advanced/metastatic patients, respectively. The secondary purposes is to determine the sensitivity of the CYBRID Score for predicting in-vivo clinical response based on surgical response or RECIST 1.1 for neoadjuvant and locally advanced/metastatic patients, respectively.

NCT ID: NCT05038254 Recruiting - Clinical trials for Stage IV Pancreatic Cancer AJCC v8

Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events

Start date: May 12, 2021
Phase: N/A
Study type: Interventional

This clinical trial studies if enhanced outpatient symptom management with telemedicine and remote monitoring can help reduce acute care visit due to chemotherapy-related adverse events. Receiving telemedicine and remote monitoring may help patients have better outcomes (such as fewer avoidable emergency room visits and hospitalizations, better quality of life, fewer symptoms, and fewer treatment delays) than patients who receive usual care.

NCT ID: NCT04785287 Active, not recruiting - Clinical trials for Advanced Malignant Solid Neoplasm

Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

Start date: March 29, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects of anti-CTLA4-NF monoclonal antibody (mAb) (BMS986218), nivolumab, and stereotactic body radiation therapy in treating patients with solid malignancies that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as anti-CTLA4-NF mAb (BMS-986218) and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving -CTLA4-NF mAb (BMS986218), nivolumab, and stereotactic body radiation therapy may kill more tumor cells.

NCT ID: NCT03028311 Active, not recruiting - Clinical trials for Stage IV Liver Cancer

Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer

Start date: January 9, 2017
Phase: Phase 1
Study type: Interventional

This clinical trial studies the side effects and best way to perform yttrium Y-90 radioembolization in treating patients with liver cancer that has spread to other places in the body (metastatic). Yttrium Y-90 radioembolization is a therapy that injects radioactive microspheres directly into an artery that feeds liver tumors to cut off their blood supply. Performing yttrium Y-90 radioembolization in a single session may make treatment faster, minimize patient travel, and decrease the overall cost of the procedure.